Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Beynarovich A, Lepik K, Mikhailova N, Borzenkova E, Volkov N, Moiseev I, Zalyalov Y, Kondakova E, Kozlov A, Stelmakh L, Pirogova O, Zubarovskaya L, Kulagin A, Afanasyev B. Beynarovich A, et al. Among authors: borzenkova e. Int J Hematol. 2022 Sep;116(3):401-410. doi: 10.1007/s12185-022-03355-3. Epub 2022 May 5. Int J Hematol. 2022. PMID: 35511399
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV, Lepik KV, Volkov NP, Kotselyabina PV, Borzenkova ES, Popova MO, Beynarovich AV, Baykov VV, Kozlov AV, Moiseev IS, Mikhailova NB, Kulagin AD. Fedorova LV, et al. Among authors: borzenkova es. Int J Clin Oncol. 2022 Mar;27(3):626-632. doi: 10.1007/s10147-021-02085-6. Epub 2021 Nov 26. Int J Clin Oncol. 2022. PMID: 34826011 Free PMC article.
Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults.
Moiseev IS, Morozova EV, Bykova TA, Paina OV, Smirnova AG, Dotsenko AA, Borzenkova ES, Galimov AN, Gudognikova YV, Ekushov KA, Kozhokar PV, Osipova AA, Pirogova OV, Rudakova TA, Klimova OU, Tcvetkov NY, Kulagin EA, Surkova EA, Lapin SV, Rodionov GG, Moiseev SI, Serov YA, Zubarovskaya LS, Afanasyev BV. Moiseev IS, et al. Among authors: borzenkova es. Bone Marrow Transplant. 2020 Jul;55(7):1379-1387. doi: 10.1038/s41409-020-0834-4. Epub 2020 Feb 18. Bone Marrow Transplant. 2020. PMID: 32071418
Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
Moiseev I, Bondarenko S, Morozova E, Vlasova Y, Dotsenko A, Epifanovskaya O, Babenko E, Botina A, Baykov V, Surkova E, Lapin S, Beynarovich A, Borzenkova E, Golosgchapov O, Kanunnikov M, Kudyasheva O, Ovechkina V, Pirogova O, Porunova V, Rudakova T, Smikova O, Smirnova A, Afansyev B. Moiseev I, et al. Among authors: borzenkova e. Transplant Cell Ther. 2021 Jul;27(7):601.e1-601.e7. doi: 10.1016/j.jtct.2021.03.032. Epub 2021 May 7. Transplant Cell Ther. 2021. PMID: 33845259 Free article.
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.
Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV. Lepik KV, et al. Among authors: borzenkova es. Hemasphere. 2020 Jun 8;4(3):e401. doi: 10.1097/HS9.0000000000000401. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647803 Free PMC article.
Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.
Lepik KV, Mikhailova NB, Moiseev IS, Kondakova EV, Tsvetkova LA, Zalyalov YR, Borzenkova ES, Babenko EV, Baykov VV, Markova IV, Afanasyev BV. Lepik KV, et al. Among authors: borzenkova es. Leuk Lymphoma. 2019 Sep;60(9):2316-2319. doi: 10.1080/10428194.2019.1573368. Epub 2019 Feb 4. Leuk Lymphoma. 2019. PMID: 30712423 No abstract available.